Artal Group S.A. Lyell Immunopharma, Inc. Transaction History
Artal Group S.A.
- $101 Million
- Q4 2024
Shares
1 transactions
Others Institutions Holding LYEL
# of Institutions
108Shares Held
171MCall Options Held
7.7KPut Options Held
15.3K-
Mwg Management Ltd. Washington, DC20.2MShares$11.7 Million17.35% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$8.75 Million42.56% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$8.75 Million14.08% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$7.83 Million0.0% of portfolio
-
Decheng Capital LLC Menlo Park, CA11.9MShares$6.91 Million1.63% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $144M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...